Case reports

British Heart Journal, 1975, 37, 668–671.

Advanced heart block aggravated by carbamazepine

B. Beermann, O. Edhag, and H. Vallin
From the Department of Medicine, Serafimerlasarettet, Stockholm, Sweden

This report presents a serious adverse reaction to the anticonvulsant compound carbamazepine. A woman was admitted to hospital for recurrent attacks of syncope. She suffered from atrioventricular block of the Mobitz type II. Carbamazepine suppressed the conduction in her already defective Purkinje fibres and induced ventricular stand-still with subsequent Adams-Stokes attacks.

Several drugs, used for purposes other than for cardiac disease, have been shown to have profound actions on the heart. Among these compounds, the anticonvulsant drug diphenylhydantoin has become an important antiarrhythmic agent with minor effects on atrioventricular conduction (Caracta et al., 1973). We have recently observed that carbamazepine, another anticonvulsant drug, has disturbing effects on His-Purkinje conduction.

The aim of this paper is to report a patient in whom carbamazepine induced complete heart block with subsequent Adams-Stokes attacks.

Case report

The patient was a 66-year-old woman. She had had trigeminal neuralgia at the age of 31 years. For six years she had symptoms of slight heart failure and was intermittently treated with digoxin and frusemide. Chest x-ray, three years earlier, showed slight enlargement of her heart, confined mainly to the left ventricle. Her electrocardiogram at that time showed sinus rhythm with a PR interval of 0.20 s and left anterior fascicular block.

For three years the patient had suffered from right-sided trigeminal neuralgia for which she had been prescribed carbamazepine in a dosage of 200 to 400 mg twice or three times daily. This medication gave complete relief of her pain.

Six months before admission to hospital her doctor observed bradycardia, 40 to 50 beats/min and withdrew digoxin. No electrocardiographic record was made. Some weeks later, the patient had a brief syncopal attack. At that time, she had been taking greater amounts of carbamazepine than usual because of increasing neuralgia. Despite the syncope, the patient did not contact any doctor. During the 3 months before her admission into hospital the patient had more or less continuous bradycardia, vertigo, and pronounced dyspnoea.

Ten days before admission the patient was examined by a private practitioner who diagnosed heart failure as well as bradycardia, 40 beats/min. She was prescribed the cardiac glycoside proscillaridin in a dosage of 0.25 mg four times daily and atropine 0.5 mg three times daily. After that change in medication her dyspnoea and vertigo increased. One day before admission to hospital the patient had another syncopal attack and was, at that time, unconscious for approximately 10 minutes. During that day she had taken high doses of carbamazepine but did not remember how many tablets. She was referred to Serafimerlasarettet.

Physical examination in hospital revealed bradycardia with a frequency of 40/min, but no other abnormality was detected. Laboratory examination demonstrated slight anaemia; Hb 11.8 g/100 ml. Electrolytes (Na+, K+, Cl−, HCO3−, Ca++) S-GOT, S-GPT, and LDH were within normal ranges, as was serum creatinine and bilirubin. Electrocardiogram showed 2:3:1 atrioventricular block of the Mobitz type 2 and left anterior fascicular block. Chest x-ray was unchanged from that of three years previously and showed slight cardiac enlargement. The patient was prescribed frusemide 40 mg daily, potassium chloride 0.75 g t.d.s., and carbamazepine 200 mg q.d.s. Proscillaridin and atropine were withdrawn. Four days after admission to hospital the patient had a syncopal attack during which she was pulseless. She recovered after some minutes. The electrocardiogram after recovery showed an unchanged picture, with 2:3:1 atrioventricular block.

Transvenous pacemaker stimulation was initiated. The initial stimulation threshold was 0.5 V (0.4 mA). The patient’s trigeminal neuralgia got worse and the dose of carbamazepine was increased to 400 mg three times daily. During threshold measurements on two subsequent days the electrocardiographic registrations showed regular atrial but no ventricular escape rhythm during an interval of up to 10.5 sec. On the suspicion that carbamazepine had induced the block and suppressed
the idioventricular activity, the drug was withdrawn. Two days later the patient had 2:1 atrioventricular block of the Mobitz type 2 (Fig. 1a). His bundle electrogram indicated normal AH conduction and an intermittent block located distal to the bundle of His (Fig. 2a). The patient was given 400 mg carbamazepine orally. Electrocardiogram was registered one hour later and showed 3-4:1 atrioventricular block of Mobitz type 2. Prescription of 400 mg carbamazepine 3 times daily, again induced complete heart block. Atrial but no ventricular activity was seen (Fig. 1b). His bundle electrogram still showed normal AH conduction (Fig. 2b). Thus, the block was induced distal to the bundle of His. The drug was withdrawn and the block reverted to 2:1 atrioventricular block. Carbamazepine was regarded as a dangerous compound for the patient in the event of trouble with the pacemaker system and therefore the patient was given diphenylhydantoin 0.1 g three times daily. This drug had a good effect on her trigeminal neuralgia and no negative effects on her atrioventricular conduction.

The patient was discharged from hospital. On routine check-up one week later, pacemaker dysfunction was observed. Chest x-ray revealed that the pacemaker electrode had been dislodged to the superior vena cava. Since her discharge, the patient has not experienced any dizziness nor has she had any syncopal attacks.

**Discussion**

This patient fainted during periods when she had a high intake of carbamazepine, suggesting suppressing effects of the drug on the atrioventricular conduction with subsequent Adams-Stokes attacks. However, the patient had used cardiac glycosides at least on one of the occasions, which might have influenced the atrioventricular conduction. The patient mainly had 2:1 atrioventricular block of Mobitz type 2 during the hospital stay when she was free of carbamazepine. There were no signs of delayed conduction through the atrioventricular node. The atrioventricular block was located distal to the bundle of His. One hour after oral administration of 400 mg carbamazepine 3-4:1 atrioventricular block II was registered. Prescription of the anticonvulsant compound in the dosage of 400 mg three times daily induced complete heart block, with no demonstrable ventricular activity. His bundle electrogram showed that the atrioventricular conduction block was induced in the already injured part of the conduction system.

This case history shows without any reasonable doubt that carbamazepine had negative effects on the patient's atrioventricular conduction. It also seems probable that carbamazepine decreased the ventricular automaticity, as judged by the observation of lack of ventricular activity, when atrioventricular conduction was completely inhibited.

The negative effects on atrioventricular conduction and possibly on ventricular automaticity are in accordance with the findings by Steiner et al. (1970), who studied the electrophysiological effects of carbamazepine on dog hearts. The drug prolonged atrioventricular conduction moderately
in vivo but did not affect the interatrial or the intra-
ventricular conduction. The compound restored
sinus rhythm in dogs suffering from ventricular
arrhythmias induced by digitalis. In vitro experi-
ments demonstrated depression of phase 4 depolar-
ization and decrease in firing rate of spontaneously
active Purkinje fibres.

The present adverse reaction to carbamazepine
in man does not appear to have been reported before.
The most common side effects of this drug are
ataxia, drowsiness, and various allergic reactions
(Meyler and Herxheimer, 1972). The lack of reports
of cardiac effects after oral administration of car-
bamazepine to patients indicates that a defective
conduction system might be a necessary prerequisite
for induction of atrioventricular block by the drug.
It is also possible that this effect is more often
brought about by therapeutic doses of the drug in
patients with latent damage of the conductive
system as is the case with digitalis (Edhag, 1969).

The present case indicates that carbamazepine
should be prescribed with caution to patients with a
defective conduction system. To such patients
diphenylhydantoin might be prescribed without
negative effects on the conduction system as was the
case in this patient.

References
Caracta, A. R., Damato, A. N., Josephson, M. E., Ricciutti,
diphenylhydantoin. Circulation, 47: 1234.
Scandinavica, 186, Suppl. 502.
Meyler, L., and Herxheimer, A. (1972). (Eds.) Side Effects
Amsterdam.
Steiner, C., Wit, A. L., Weiss, M. B., and Damato, A. N.
(1970). The antiarrhythmic actions of carbamazepine
(Tegretol). Journal of Pharmacology and Experimental
Therapeutics, 173, 323.

Requests for reprints to Dr. B. Beermann, Department
of Medicine, Serafimerlasaretet, S-112 83 Stockholm, Sweden.